

Product Information

CompoZr® Disease Model Cell Lines MCF10A Cells Rictor -/-

Catalog Number **CLLS1053**

Storage Temperature -196 °C (liquid nitrogen)

Product Description

CompoZr® zinc finger nuclease (ZFN) technology is a fast and reliable way to manipulate the genome in a targeted fashion. ZFNs are synthetic proteins engineered to bind DNA at a sequence-specific location and create a double strand break (www.compozrzfn.com). The cell's natural machinery repairs the break in one of two ways: non-homologous end joining or homologous recombination. The non-homologous end joining pathway resulted in deletions at the Rictor locus in exon 1 (see Figure 1). Single cell clones were isolated and followed for more than twenty passages to establish stable cell lines.

While the targeted gene in this cell line is diploid, ZFN-mediated gene knockout technology is not limited to diploid targets, allowing the researcher to pursue many of the polyploid cell lines often characteristic of cancer. Modified cell lines provide the basis for the development of various assays for compound screening. Here, the target gene is disrupted by an out-of-frame deletion of 10 and 71 bases on their respective alleles.

Rictor is part of the mTORC2 complex that forms with mTOR and is involved in detecting growth factor signaling and stimulating cell proliferation.^{1,2} The mTOR pathway has been found to be deregulated in a variety of cancers. First generation inhibitors of mTOR such as rapamycin, act through binding the protein FKBP12 to form a complex that inhibits mTOR activity in the mTORC1 complex. Second generation inhibitors that block the ATP site affect both mTORC1 and mTORC2 and show greater potency.¹ The mTOR pathway has been found to be activated in breast cancer,³ with drugs currently in development for treatment.⁴ While there is evidence the mTOR pathway in general is involved in metastasis,⁵ Rictor specifically appears to be involved in metastasis of breast cancer cells and shows an interaction with PKC ζ that influences chemotaxis.⁶

Rictor also appears to interact with ILK leading to regulation of AKT phosphorylation and effects on cell survival.⁷ Knockout of the Rictor in the MCF10A cell line will allow further study of its metastatic role.

For further information and to download sequence of modified locus, go to the website:
www.wherebiobegins.com/biocells

Components

MCF10A mutant cell line with Rictor gene knocked out	1 vial
Catalog No. CLL1053	

Parental mammary epithelial cell line (ATCC® Catalog No. CRL-10317™)	1 vial
Catalog No. CLL1040	

1 vial of MCF10A cells contains ~2 × 10⁶ cells.

The cryoprotectant medium used is Cell Freezing Medium-DMSO 1×, Catalog No. C6164.

Figure 1.

Creation of Rictor Knockout in MCF10A Cells

Site-specific deletion at the Rictor Locus in MCF10A cell line

Allele 1 – 10 bp deletion

GTTGTGACTGAAACCCGTCAATATGGCGGCG**ATC**
GGCCGCGGCCGCtctct**GAAGAACCTCCG**AGTACGA
GGTAAGCCCCGCTGCAACCCTCACTCCCCACCGCC
CGGCGCCCGCCACCCCTGGCACTTGCCTTCCCT
GGCCCTGGGTTGGGAGCGAGCCGGGGCGCTGG
CCGGAGCCAGGGCAGCCGCAGCTGGCCTGCGAG
CC**AATCCTAATTGGGGCTGTGTCTG**TTTCGCGC
AGGGCGGAATGACAGCGGCG

Allele 2 – 71 bp deletion

GTTGTGACTGAAACCCGTCAATATGGCGGCG**ATC**
GGCCGCGGCCGCctct**GAAGAACCTCCG**AGTACGA
GGTAAGCCCGCTGCAACCCTCACTCCCCACCGCC
CGGCGCCCGCCACCCCTGGCACTTGCCTTCCCCT
GGCCCTGGGTTGGGGAGCGAGCCGGGGCGCTGG
CCGGAGCCAGGGCAGCCGCAGCTGGCCTGCGAG
CC**AATCCTAATTGGGGCTGTGTCTG**TTTCGCGC
AGGGCGGAATGACAGCGGCG

Schematic of the genomic sequence at the target region (exon 1) recognized by the ZFN pair, the resulting deletion, and the CEL-I primer sequences:

CEL-I Primers - **Bolded & underlined**

ZFN binding site - **UPPER CASE, BOLDED RED**

ZFN cut site - **lower case red**

Deletion - **yellow highlighted**

Genotype: del 10/del 71 (heterozygous out-of-frame deletion occurs in exon 1).

Cell Line Description

Organism: *Homo sapiens* (human)

Tissue: mammary gland; breast

Age: 36 years

Gender: Female

Ethnicity: Caucasian

Morphology: Epithelial

Growth properties: Adherent

DNA profile

Short Tandem Repeat (STR) analysis:

Amelogenin: X

CSF1PO: 10,12

D13S317: 8,9

D16S539: 11,12

D5S818: 10,13

D7S820: 10,11

THO1: 8,9.3

TPOX: 9,11

vWA: 15,17

Parental Cell Line: ATCC Catalog No. CRL-10317

Note: Please see CRL-10317 product datasheet from ATCC for additional information about the origin of these cell lines. Cytogenetic information is based on initial seed stock at Sigma Life Science. Cytogenetic instability has been reported in the literature for some cell lines.

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Biosafety Level: 1

This cell line is not known to harbor an agent known to cause disease in healthy adult humans. Handle as a potentially biohazardous material under at least Biosafety Level 1 containment. The parental cell line, MCF10A, was obtained from ATCC. All animal products used in the preparation of the knockout line and maintenance of both, parental and knockout clone, have been screened negative by 9CFR for adventitious viral agents. Cell lines derived from primate lymphoid tissue may fall under the regulations of 29 CFR 1910.1030 Bloodborne Pathogens. Appropriate safety procedures are recommended to be used when handling all cell lines, especially those derived from human or other primate material. Detailed discussions of laboratory safety procedures have been published.⁸⁻¹¹

Storage/Stability

Upon receiving a shipment of frozen cells it is important the end user gives the shipment attention without delay. To ensure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70 °C. Storage at -70 °C will result in loss of viability.

Precaution: It is recommended that protective gloves and clothing always be used, and a full face mask always be worn when handling frozen vials. It is **important to note that some vials leak when submersed in liquid nitrogen** and will slowly fill with liquid nitrogen. Upon thawing, the conversion of the liquid nitrogen back to the gas phase may result in the rapid expansion of the vessel, potentially blowing off its cap with dangerous force creating flying debris.

At the time a cell line is ordered, end users should also consider the culture conditions for the new cell line and make sure the appropriate medium will be available when the cells arrive.

Preparation Instructions

Complete Medium

Dulbecco's Modified Eagle's Medium (DMEM)/Ham's Nutrient Mixture F12 (1:1) with 2.5 mM L-glutamine, 5% horse serum, 10 µg/mL human insulin, 0.5 µg/mL hydrocortisone, 10 ng/mL EGF, and 100 ng/mL cholera toxin. This medium is formulated for use with a 5% CO₂ in air atmosphere.

Medium Components

DMEM/F12, Catalog No. 51448C

Cholera Toxin from *Vibrio cholerae*, Catalog No. C8052

Epidermal Growth Factor, Catalog No. E9644

Horse Serum, Catalog No. H1270

Hydrocortisone Solution, 50 µM, Catalog No. H6909

Insulin Solution, Catalog No. I9278

To make the complete growth medium combine the following:

1. 1 liter of DMEM/F12
2. 108 µL of Cholera toxin solution (1 mg/mL), prepared by dissolving Catalog Number C8052 in sterile water. Store solution at 2–8 °C.
3. 10.8 µL of EGF solution (1 mg/mL), prepared by dissolving Catalog Number E9644 in 10 mM acetic acid, followed by 0.2 µm filtration. Store the solution in aliquots at –20 °C.
4. 50 mL of horse serum
5. 29 mL of Hydrocortisone Solution, 50 µM
6. 1.08 mL of Insulin Solution

Procedure

Thawing of Frozen Cells

1. Thaw the vial by gentle agitation in a 37 °C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (~2 minutes).
2. Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
3. Transfer the vial contents to a centrifuge tube containing 9.0 mL of Complete Medium and spin at ~125 × g for 5–7 minutes.

4. Resuspend cell pellet with the Complete Medium and dispense into a 25 cm² culture flask. It is recommended to begin the culture in a 25 cm² flask as the initial adaptation and expansion of the cells is more rapid in a denser environment. It is important to avoid excessive alkalinity of the medium during recovery of the cells. It is suggested, prior to the addition of the vial contents, the culture vessel containing the Complete Medium be placed into the incubator for at least 15 minutes to allow the medium to reach its normal pH (7.0–7.6) and temperature (37 °C).
5. Incubate the culture at 37 °C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended for the Complete Medium.

Subculturing Procedure

Volumes used in this procedure are for a 75 cm² flask; proportionally reduce or increase volume of dissociation medium for culture vessels of other sizes.

1. Remove and discard culture medium.
2. Briefly rinse the cell layer with Trypsin-EDTA solution (Catalog No. T3924).
3. Then, add 2.0–3.0 mL of Trypsin-EDTA solution to the flask and incubate at 37 °C for 5–15 minutes (examine the flask every 5 minutes in order to minimize exposure to the trypsin-EDTA). This should remove the cells from the cultureware and yield single cells.
4. When cells are detached, add 6.0–8.0 mL of Complete Medium and aspirate cells by gentle pipetting.
5. Gently pellet the cells, remove the supernatant, and resuspend to 6–8 mL with Complete Medium.
6. Add appropriate aliquots of the cell suspension into new culture vessels.
Subcultivation Ratio: 1:2 (or less in order to maintain a higher cell density to promote cell growth).
7. Incubate cultures at 37 °C.

Note: MCF10A parental cells require longer time for trypsin digestion than what is typical. However, it is recommended when passing cells to check every 5 minutes in order to minimize exposure time to trypsin. More information on enzymatic dissociation and subculturing of cell lines is available in the literature.¹²

References

1. Foster, K.G., andingar, D.C., mTOR: Conducting the cellular signaling symphony. *Journal of Biological Chemistry*, **285**, 14071-14077 (2010).
2. Sparks, C.A., and Guertin, D.A., Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. *Oncogene*, **29**, 3733-44 (2010).
3. Alvarez, R.H. et al., Emerging targeted therapies for breast cancer. *Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology*, **28**, 3366-79 (2010).
4. O'Regan, R., and Hawk, N.N., mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy. *Expert opinion on therapeutic targets*, (2011).
5. Zhou, H., and Huang, S., mTOR signaling in cancer cell motility and tumor metastasis. *Critical reviews in eukaryotic gene expression*, **20**, 1-16 (2010).
6. Zhang, F. et al., mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis. *Cancer research*, **70**, 9360-70 (2010).
7. McDonald, P.C. et al. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. *Cancer research*, **68**, 1618-24 (2008).
8. Centers for Disease Control (1999), Biosafety in Microbiological and Biomedical Laboratories Human Health Service Publication No. (CDC) 93-8395. U.S. Dept. of Health and Human Services; 4th Edition U.S. Government Printing Office Washington D.C. The entire text is available online at www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm
9. Fleming, D.O. et al., (1995) *Laboratory Safety: Principles and Practice*. Second edition, ASM press, Washington, DC.
10. Hay, R.J. et al., eds. (1992), *ATCC Quality Control Methods for Cell Lines*. 2nd edition, Published by ATCC.
11. Caputo, J.L., Biosafety procedures in cell culture. *J. Tissue Culture Methods*, **11**, 223-227 (1988).
12. Freshney, R.I., Chapter 10 in *Culture of Animal Cells, a manual of Basic Technique* by, 3rd edition, published by Alan R. Liss, (NY, NY: 1994).

Additional product and technical information can be obtained from the catalog references and the Sigma Life Science Website (www.wherebiobegins.com/biocells).

Please see the Label License Agreement (LLA) for further details regarding the use of this product. The LLA is available on our website at www.wherebiobegins.com/biocells

These cells are distributed for research purposes only. Sigma Life Science requires that individuals contemplating commercial use of any cell line first contact us to negotiate an agreement. Third party distribution of this cell line is prohibited.

CompoZr is a registered trademark of Sigma-Aldrich Co. LLC.
ATCC is a registered trademark of American Type Culture Collection.
CRL-10317 is a trademark of American Type Culture Collection.

ADM,MAM 01/12-1